Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study

Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study

Abstract Background Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children re...

Full description

Bibliographic Details
Main Authors: Yuzaburo Inoue, Kanako Mitsunaga, Takeshi Yamamoto, Koki Chiba, Fumiya Yamaide, Taiji Nakano, Yoshinori Morita, Akiko Yamaide, Shuichi Suzuki, Takayasu Arima, Ken-ichi Yamaguchi, Minako Tomiita, Naoki Shimojo, Yoichi Kohno
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Osteoporosis
Bone loss
Alendronate
Glucocorticoid
Childhood-onset rheumatic disease
Online Access:http://link.springer.com/article/10.1186/s12969-018-0258-5

Internet

http://link.springer.com/article/10.1186/s12969-018-0258-5

Similar Items